13908-58-2

Basic information

• Product Name: N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA
• Synonyms: N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA;N-(2-Chloroethyl)-N'-pyridin-3-ylurea;1-(2-Chloroethyl)-1-(pyridin-3-yl)urea
• CAS NO: 13908-58-2
• Molecular Formula: C₈H₁₀ClN₃O
• Molecular Weight: 199.6375
• Mol File: 13908-58-2.mol

Chemical Properties

• Melting Point: 143-144
• Boiling Point: 322.5 °C at 760 mmHg
• Flash Point: 148.9 °C
• Appearance: /
• Density: 1.309g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA(13908-58-2)
• EPA Substance Registry System: N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA(13908-58-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 13908-58-2(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA is used as a chemotherapy agent for its potential antineoplastic activity. It is particularly effective in inhibiting the growth of various types of cancer cells by disrupting their DNA replication and repair mechanisms.
Used in Combination Therapy:
N-(2-CHLOROETHYL)-N'-(3-PYRIDINYL)UREA is also being investigated for its potential use in combination with other chemotherapy drugs. This combination therapy aims to improve cancer treatment outcomes by enhancing the efficacy of existing treatments and overcoming drug resistance in cancer cells.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 1943-83-5 2-chloroethyl isothiocyanate 

Downstream Products

• 55661-37-5 1-(2-Chloroethyl)-1-nitroso-3-(3-pyridino)-urea 

Relevant articles and documents

Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors

When skeletons of Win compounds were used as templates, computer-assisted drug design led to the identification of a novel series of imidazolidinone derivatives with significant antiviral activity against enterovirus 71 (EV 71), the infection of which had

Inhibitors of CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors

A novel class of arylthiourea HCV inhibitors bearing various functionalities, such as cyclic urea, cyclic thiourea, urea, and thiourea, on the alkyl linker were designed and synthesized. Herein we report the synthesis and structure-activity relationships

Imidazolidinones as brain activators

This invention relates to imidazolidinone compounds of the formula STR1 wherein Q is methylene group or a single bond: R is a heterocyclic group selected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3-thiazolyl which may be unsubstituted or with a substituent selected from the group consisting of lower alkyl, lower alkoxy and halogen atom, wherein R is bonded to Q or, when Q is a single bond, to the imidazolidinone ring, through the carbon atom of R; the ring A is an unsubstituted phenyl or a substituted phenyl having 1 or 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, halogen, lower alkylthio, trihalogeno-lower alkyl and nitro; Y is vinylene group or ethynylene; m is a integer from 1 to 6 and n is 0, 1 or 2, or a pharmacetically acceptable salt thereof. These compounds aer useful as cerebral activators, anti-depressants and nootropic drugs.

Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.

Nitrosourea derivatives 18-22 which utilize either a piperidine or pyridine ring as a carrier group were synthesized and evaluated for anticancer activity. N'-(1-Benzyl-4-piperidinyl)-N-(2-chloroethyl)-N-nitosourea hydrogen maleate (19) exhibited good activity against intracranial L1210 leukemia as well as the mouse ependymoblastoma brain tumor system. Compound 19 exhibited comparable activity in the Lewis lung carcinoma system to N,N'-bis(2-chloroethyl)-N-nitrosourea. Replacement of the N-benzyl group in both the 3-piperidinyl- and 4-piperidinylnitrosoureas resulted in less active compounds in all tumor systems tested. The 3-pyridylnitrosourea 22 was inactive in the L-1210 leukemia system.